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AbstrAct
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is largely incurable due to 
late diagnosis. Superior early detection biomarkers are critical to improving PDAC 
survival and risk stratification. 
Experimental Design: Optimized meta-analysis of PDAC transcriptome datasets 
identified and validated key PDAC biomarkers. PDAC-specific expression of a 5-gene 
biomarker panel was measured by qRT-PCR in microdissected patient-derived FFPE 
tissues. Cell-based assays assessed impact of two of these biomarkers, TMPRSS4 and 
ECT2, on PDAC cells.
Results: A 5-gene PDAC classifier (TMPRSS4, AHNAK2, POSTN, ECT2, SERPINB5) 
achieved on average 95% sensitivity and 89% specificity in discriminating PDAC from 
non-tumor samples in four training sets and similar performance (sensitivity = 94%, 
specificity = 89.6%) in five independent validation datasets. This classifier accurately 
discriminated PDAC from chronic pancreatitis (AUC = 0.83), other cancers (AUC = 
0.89), and non-tumor from PDAC precursors (AUC = 0.92) in three independent 
datasets. Importantly, the classifier distinguished PanIN from healthy pancreas in 
the PDX1-Cre;LSL-KrasG12D PDAC mouse model. Discriminatory expression of the PDAC 
classifier genes was confirmed in microdissected FFPE samples of PDAC and matched 
surrounding non-tumor pancreas or pancreatitis. Notably, knock-down of TMPRSS4 
and ECT2 reduced PDAC soft agar growth and cell viability and TMPRSS4 knockdown 
also blocked PDAC migration and invasion. 
Conclusions: This study identified and validated a highly accurate 5-gene PDAC 
classifier for discriminating PDAC and early precursor lesions from non-malignant 
tissue that may facilitate early diagnosis and risk stratification upon validation in 
prospective clinical trials. Cell-based experiments of two overexpressed proteins 
encoded by the panel, TMPRSS4 and ECT2, suggest a causal link to PDAC development 
and progression, confirming them as potential therapeutic targets.
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IntroductIon
Pancreatic ductal adenocarcinoma (PDAC), the third 
leading cause of cancer death in the United States (US), 
is marked by an exceptionally high mortality rate [1], 
due to late diagnosis when curative resection is no longer 
possible. Although imaging and endoscopic approaches 
assist with PDAC staging, their efficacy is limited for 
screening and risk stratification, and PDAC diagnosis 
can be limited by indeterminate pathologic evaluation 
of biopsy specimens [2]. Therefore, superior biomarkers 
for earlier detection of PDAC and for improved risk 
stratification are imperative for improving PDAC survival. 
The magnitude of the need for better PDAC 
biomarkers is large: 330,000 patients worldwide die 
from PDAC annually and many must face uncertainty of 
diagnostic tests or the malignant potential of incidentally 
discovered pancreatic lesions and PDAC risk factors. For 
example, the limits of cytologic examination of pancreatic 
mass lesions often preclude definitive diagnosis of PDAC, 
particularly in the presence of chronic pancreatitis and 
when an on-site cytopathologist is not available [3, 4]. 
Moreover, rapid improvements in imaging quality and the 
number of imaging procedures (26 million annually in the 
US) have led to a rise in identification of potential PDAC 
precursor lesions such as intraductal papillary mucinous 
neoplasms (IPMNs) and mucinous cystic neoplasms 
(MCNs). Although resection of precursor lesions is 
associated with better survival, it is often uncertain which 
lesions will progress to invasive cancer and morbidity and 
mortality of surgery can be high [5]. Accurate biomarkers 
to aid risk stratification would greatly improve the current 
diagnostic and decision-making quandary for these 
patients. Similarly, accurate biomarkers are greatly needed 
to improve screening, particularly for those who may be 
at increased risk of developing PDAC: family history of 
PDAC, hereditary syndromes, chronic pancreatitis, type 3c 
diabetes, smokers, BRCA2 carriers, etc. [6]. 
Several serum-based (CA19-9, CA125) and tissue-
specific (macrophage inhibitory cytokine-1, K-ras, 
mesothelin, PSCA, mucins, SMAD4, p53 mutations) 
proteins have been tested as potential PDAC diagnostic 
biomarkers. All have failed to demonstrate the accuracy 
needed for early detection or screening [7]. CA19-9 is 
used clinically to monitor PDAC response to therapy, but 
its utility for screening and risk-assessment is limited: it 
can be elevated in benign intra-abdominal processes and 
normal when PDAC tumors are small, the time when 
resolving diagnostic uncertainty is most important [8]. 
The urgent need for improved PDAC diagnosis 
has spurred a number of studies aimed at identifying 
differentially expressed genes in PDAC. However, no 
transcriptome data has yet translated into a clinically 
useful biomarker. Integration of the literature on 
candidate PDAC biomarkers resulted in identification of 
several thousand differentially expressed PDAC genes 
[9, 10]. The relevance of these genes for PDAC remains 
unclear due to inherent statistical limitations of the 
applied approaches combined with batch effects, variable 
techniques and platforms, and varying analytic methods 
[11]. Lack of concordance of published gene signatures 
of individual microarray studies due to variability in 
analytical strategies makes comparative analysis difficult 
when standard approaches are used [11].
One alternative to overcome the limitations of 
analyzing individual microarray datasets or multiple 
datasets that have been processed and normalized 
by different approaches is meta-analysis of multiple 
transcriptional profiling studies applying identical 
analytics that can generate gene signatures with increased 
reproducibility and sensitivity, revealing biological insight 
not evident in the original datasets [12]. The increased 
statistical power of this approach may identify a more 
reliable transcriptome signature by detecting potentially 
important genes missed in a single study or in an analysis 
of multiple studies using divergent analytical methods 
and eliminating false positives [11]. We now report the 
identification of a 5-gene PDAC classifier based on our 
meta-analysis of publicly available PDAC microarray 
datasets that accurately discriminates PDAC and early 
PDAC precursors from benign pancreatic lesions and 
healthy controls. We demonstrate validation of these 5 
genes as PDAC-specific in FFPE samples from patients 
with PDAC, providing strong support for the predicted 
diagnostic performance of our 5-gene PDAC classifier.
results
Dataset identification and meta-analysis strategy
To identify biomarkers that accurately discriminate 
between PDAC and normal pancreas or benign pancreatic 
lesions, we selected publicly available transcriptional 
profiling datasets for meta-analysis. These datasets were 
divided into training sets for development of a PDAC 
biomarker classifier and independent validation sets (see 
overview of meta-analysis strategy in Figure 1).
Among the publicly available microarray 
repositories, we selected four transcriptional profiling 
datasets of normal pancreas and PDAC tissue samples 
as training sets (Figure 1 and Table 1A), including 
two datasets from microdissected pancreatic tissue 
(GSE18670: 6 normal, 6 PDAC; E-MEXP-950: 9 
normal, 13 PDAC) and two datasets from whole tissue 
(GSE15471: 35 normal, 35 PDAC; GSE16515: 14 
normal, 36 PDAC) (Table 1A). In Phase I of independent 
validation, performance of the optimized PDAC biomarker 
panel was validated on five additional datasets (Table 1B). 
Phase I Validation was restricted to Affymetrix datasets 
from clinical samples similar to the training sets, namely 
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comparison of normal versus PDAC samples (two datasets: 
GSE32676: 7 normal, 25 PDAC; GSE28735: 45 normal, 
45 PDAC), only PDAC samples (2 datasets: GSE9599: 
36 PDAC; E-MEXP-2894: 18 PDAC) and only normal 
pancreas tissue (1 dataset: E-TABM-145: 145 normal). In 
Phase II Validation, PDAC biomarker panel performance 
was tested on four additional independent datasets 
that compared results from: i) PDAC versus normal 
pancreatic tissue on Agilent microarrays (GSE11838: 
4 normal, 28 PDAC), ii) PDAC versus other cancers 
(breast, colon, liver, lung, prostate) (GSE12630: 25 other 
cancers, 11 PDAC), iii) PDAC versus chronic pancreatitis 
(E-MEXP-1121: 9 pancreatitis, 6 PDAC), and iv) normal 
pancreas versus PDAC precursor lesions (IPMN with low- 
to intermediate-grade dysplasia (LIGD-IPMN, previously 
called intraductal papillary-mucinous adenoma (IPMA)), 
Table 1A: Datasets used for development of PDAC classifier
Training Sets: 
dataset Normal Tumor Sample Type Platform Accession #
Set1 6 6 Enriched U133 Plus 2.0 GSE18670
Set2 9 13 Microdissected U133A E-MEXP-950
Set3 35 35 Whole Tissue Plus 2.0 GSE15471
Set4 14 36 Whole Tissue Plus 2.0 GSE16515
Number of samples reflects only the samples that were used for the meta-analysis, after removing samples with low quality, 
outlier arrays.
Table 1B: Datasets used for independent validation of PDAC classifier
Phase I Validation Sets: 
dataset Normal Tumor Sample Type Platform Accession #
V1 7 25 Whole Tissue Plus 2.0 GSE32676
V2 45 45 Whole Tissue Gene St 1.0 GSE28735
V3 0 36 Whole Tissue(Xenografts in duplicate) Plus 2.0 GSE9599
V4 0 18 Microdissected Plus 2.0 E-MEXP-2894
V5 145 0 Whole Tissue & Cell Lines(most 3 replicates) U133A E-TABM-145
Phase II Validation Sets: 
dataset Group Pancreatic Tumor Sample Type Platform Accession #
P1 6 (Normal) 15 (IPMA, IPMC, IPMN) Microdissected Plus 2.0 GSE19650
P2 9 (Pancreatitis) 6 Microdissected U133A E-MEXP-1121
C1 4 (Normal) 28 Whole Tissue Agilent GSE11838
M1 25 (other Cancers) 11 Whole Tissue U133A GSE12630
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Figure 1: Overview of meta-analysis approach for development and validation of PDAC biomarker biomarker panel.
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IPMN with high-grade dysplasia (HGD-IPMN, previously 
called intraductal papillary-mucinous carcinoma (IPMC)) 
and IPMN with associated invasive carcinoma (InvCa-
IPMN, previously called invasive cancer originating from 
IPMN) (GSE19650: 6 normal, 15 PDAC precursors (5 
LIGD-IPMN, 5 HGD-IPMN, 5 InvCa-IPMN)) (Figure 
1 and Table 1B). All datasets utilized oligonucleotide-
based microarray platforms (three versions of Affymetrix 
GeneChips and Agilent microarrays in one dataset).
Figure 2: Meta-signature of genes that are consistently differentially expressed in multiple datasets and candidate 
PDAC diagnostic biomarker panels. A. Signal to Noise ratio based heatmap of the 409 meta-signature genes. B. Description of the 
genes from the 5- and 10-gene based PDAC biomarker panels. C. Relative expression of the 10 candidate biomarker genes across all four 
training sets visualized as a heatmap. 
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Identification of PDAC biomarker candidates
Using identical normalization and statistical 
methods for each dataset, a broad range of differentially 
expressed genes was identified through empirical Bayes 
comparative meta-analysis of the raw expression data 
in the four PDAC training datasets. The number of 
differentially expressed genes ranged from 90 to 10,169 
genes (See Supplementary Table S1), totaling 11,322 
significantly differentially expressed genes in the four 
training datasets. Heatmaps for the top up- and down-
regulated genes in two of the datasets are shown in 
Supplementary Figure S1A. Venn diagram analysis of 
these differentially expressed genes identified 409 genes 
with concordant directionality to at least three of the four 
datasets (Supplementary Figure S1B). These 409 genes 
were selected for further evaluation. 
Consistent expression across these four datasets for 
each of the 409 concordant genes is demonstrated in a 
heatmap of the relative ratio of gene expression in PDAC 
compared to normal pancreas (NP) (Figure 2A), with the 
extent of overexpression or underexpression denoted by 
red or blue shading, respectively. Principal Component 
Analysis (PCA) of these 409 genes shows a dominant 
separation pattern for most of the PDAC and normal 
pancreas samples in each dataset (Supplementary Figure 
S1C). 
Canonical pathway analysis of these 409 common 
PDAC genes using Ingenuity Pathway Analysis identified 
the highest statistical enrichment of these genes in various 
cancer-related pathways linked to DNA damage (ATM 
Signaling, DNA damage-induced 14-3-3σ Signaling, 
GADD45 signaling), cell cycle (G2/M DNA damage 
checkpoint regulation, Cell cycle control of chromosomal 
replication, p53 signaling, Mitotic role of Polo-like 
kinase), and Protein kinase A signaling (Supplementary 
Figure S2). Most of these pathways play important roles 
in PDAC.
Class prediction analysis in training sets
Class prediction analysis with support vector 
machines generated a large number of PDAC classifiers 
containing 2 to 40 genes. Based on LOOCV evaluation 
in the training sets, classifiers containing 5 or 10 genes 
performed with highest accuracy. The 5-gene PDAC 
classifier (TMPRSS4, ECT2, SERPINB5, AHNAK2, 
POSTN) is a subset of the 10-gene PDAC classifier 
(TMPRSS4, ECT2, SERPINB5, AHNAK2, POSTN, 
S100P, CEACAM5, GABRP, CELA2B, CUZD1) and 
only includes genes overexpressed in PDAC (Figure 2B). 
The 10-gene PDAC classifier includes 2 genes (CELA2B, 
CUZD1) that are reduced specifically in PDAC. A heatmap 
of these 10 genes across the four training sets (Figure 2C) 
demonstrates differential expression in PDAC compared 
to normal pancreas across most of the samples. 
We performed LOOCV of the 10-gene and 5-gene 
PDAC classifier across the four training datasets in order 
to compare predictive performance and to determine 
which of these two classifiers to further evaluate on the 
independent test sets. LOOCV of the 5-gene classifier 
demonstrated overall better performance than the 10-
gene predictor for the four training sets. While for each 
of the four training datasets individually sensitivity ranges 
from 0.89-1.0 and specificity from 0.80-1.00 for the 
5-gene predictor (Figure 3A), for the 10-gene predictor 
sensitivity ranges from 0.77-1.0 and specificity from 
0.67-1.00 (Figure 3B). Comparison of the 5- and 10-gene 
PDAC classifier performance shows an average 0.95 
sensitivity and 0.89 specificity for the 5-gene classifier, 
in contrast to 0.89 sensitivity and 0.83 specificity for the 
10-gene classifier (Figure 3C). Based on this comparison 
of the 10-gene PDAC classifier to the 5-gene classifier, 
only the 5-gene classifier was further evaluated on the 
independent datasets. Random sampling based ROC 
prediction across the training sets further confirms that 
the 5-gene PDAC predictor has indeed the largest AUC 
(Figure 3D): AUC for the four datasets ranged from 0.88-
1.0 with median=0.93 (Figure 3E, demonstrates threshold 
independent performance). 
Evaluation of the GENT database that compares 
relative expression of genes between different cancers and 
their normal tissue counterparts indicates that all genes in 
the 5-gene classifier are overexpressed in PDAC relative 
to normal pancreas (Supplementary Figure S3). Each of 
these 5 genes appears also overexpressed in several other 
types of cancer (Supplementary Figure S3). 
The 5-gene PDAC classifier predicts PDAC with 
high accuracy in 9 independent validation sets
In Phase I Validation, the 5-gene PDAC classifier 
accurately predicted the class of PDAC compared to 
NP with a sensitivity of 96% and 88.89%, a specificity 
of 85.7 and 86.67%, and AUC of 0.9 and 0.8778 in two 
independent validation sets that contained 25 and 45 
PDAC and 7 and 45 normal pancreas samples, respectively 
(Figure 4A and Table 1B). These results are significantly 
better than various published values for CA19-9 [13, 14]. 
In two datasets containing exclusively PDAC samples a 
sensitivity of 97.22% and 94.5% was achieved and in a 
dataset containing 145 normal samples a specificity of 
96.5% was determined. 
In Phase II Validation, we tested the 5-gene PDAC 
classifier on a dataset that includes 6 PDAC samples and 
9 chronic pancreatitis samples (Table 1B). Specificity was 
88.9% and sensitivity 100% with an overall accuracy of 
80% and an AUC of 0.83 (Figure 4B, Left Graph). Since 
discrimination between chronic pancreatitis and PDAC is 
a key clinical challenge, the fact that the 5-gene PDAC 
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Figure 3: Performance of 5-gene and 10-gene PDAC Classifiers on training sets using leave one out cross-validation 
(LOOCV). A. Diagnostic performance of the 5-gene PDAC classifier on the four training sets of PDAC vs. normal pancreas. Sensitivity 
(Sens.) and specificity (Spec.) are indicated below each set. B. Diagnostic performance of the 10-gene PDAC classifier on the four 
training sets of PDAC vs. normal pancreas. Sensitivity (Sens.) and specificity (Spec.) are indicated below each set. C. Comparison of the 
performance of the 5- and 10-gene PDAC classifiers across the four training sets. D. AUC curve for random sampling based prediction. 
The ranking of the 5-gene PDAC classifier is indicated. E. AUC plot for 5-gene PDAC classifier across the four training sets and for the 
median of the four datasets. 
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classifier accurately distinguishes between PDAC and 
pancreatitis is a further important validation step for this 
5-gene biomarker panel. We similarly tested the 5-gene 
PDAC classifier on an independent validation dataset 
containing laser microdissected normal main pancreatic 
duct epithelial cells and neoplastic epithelial cells from 
potential PDAC precursor lesions, LIGD-IPMN, HGD-
IPMN and InvCa-IPMN [15]. The 5-gene predictor 
separated LIGD-IPMN, HGD-IPMN and InvCa-IPMN 
from normal pancreatic duct epithelial cells with 100% 
sensitivity and 83% specificity, achieving an AUC of 0.92 
(Figure 4B, Right Graph). The ROC curves for normal 
vs. PDAC, chronic pancreatitis vs. PDAC, and normal vs. 
LIGD-IPMN, HGD-IPMN, and InvCa-IPMN are shown 
in Figure 4C. 
Hierarchical clustering of this dataset demonstrates 
that the 5-gene PDAC classifier separates all potential 
PDAC precursor (LIGD-IPMN, HGD-IPMN, InvCa-
IPMN) samples from the normal pancreatic duct samples 
except for one normal sample (Figure 4D, Left Heatmap). 
Four classifier genes are consistently overexpressed in the 
PDAC precursor samples. TMPRSS4 and SERPINB5 are 
increased relative to 6 of the 7 normal pancreas samples 
in 100% of the PDAC precursor samples. AHNAK2 is 
elevated in 87% and ECT2 in 80% of the PDAC precursor 
samples. POSTN was not differentially expressed, but its 
expression had little impact on overall performance of the 
classifier in this dataset. 
Applying the 5-gene classifier to a dataset that 
included 11 PDAC samples and 25 tumor samples of 
various origins (breast, colon, liver, lung, prostate) 
resulted in sensitivity of 72.73% and specificity of 96% 
(Supplementary Figure S4A). The ROC curve is shown 
in Supplementary Figure S4A. These results suggest that 
the 5-gene classifier not only discriminates PDAC and its 
precursors from normal pancreas and benign pancreatic 
lesions, but also from several other types of cancer. 
While all datasets analyzed above were derived 
on the Affymetrix platform, one small dataset on the 
Agilent microarray platform was available (GSE11838). 
Cross-platform evaluation on this dataset of PDAC versus 
normal pancreas demonstrated a sensitivity and specificity 
of 96.4% and 75% respectively and an AUC of 0.84 
(Supplementary Figure S4B). 
The 5-gene PDAC classifier distinguishes between 
PDAC or early stage PDAC, PanIN, and healthy 
pancreas in the PDX1-Cre;LSL-KrasG12D GEM 
model of PDAC
While IPMNs have the potential to become 
malignant and progress towards PDAC, the majority of 
PDAC cases likely evolve from pancreatic intraepithelial 
neoplasia [PanIN] lesions containing Kras mutations [16]. 
While PanINs are difficult to detect in humans, various 
mutant Kras GEM models exist that spontaneously 
develop PDAC through the stages of PanIN development 
[17]. One GEM PDAC model is the PDX1-Cre;LSL-
KrasG12D model [17]. These mice develop low and high-
grade progressive ductal PanIN lesions with increasing 
age and low frequency progression to invasive PDAC 
upon activation of oncogenic Kras in the pancreas, 
phenocopying development of human PDAC [17, 18]. We 
applied an unsupervised learning approach, hierarchical 
clustering, to one available Affymetrix microarray dataset 
of three biological replicates each of normal pancreatic 
tissue, PanIN and PDAC from the PDX1-Cre;LSL-
KrasG12D mice using the expression values of our five 
PDAC classifier genes [18]. Hierarchical clustering of this 
dataset using the equivalent mouse GeneIDs demonstrated 
that all 5 genes were upregulated in both PanINs and 
PDAC compared to normal pancreas, resulting in perfect 
separation of PanINs and PDAC samples from normal 
pancreas (Figure 4D, Right Heatmap). Interestingly, 
PanINs perfectly separated from PDAC. PanIN samples 
clustered on the same main branch as the normal pancreas, 
but on a separate subbranch within this tree, suggesting 
that PanIN is indeed a stage different from normal, but in 
between normal and PDAC. POSTN exhibited the same 
level of overexpression in PanIN and PDAC compared 
to normal pancreas, TMPRSS4 was higher expressed in 
PanIN than PDAC, and ECT2, AHNAK2, and SERPINB5 
were higher expressed in PDAC (Figure 4D, Right 
Heatmap). These results provide the strongest evidence 
that the 5-gene PDAC classifier is able to discriminate 
early PDAC precursor lesions from normal pancreas 
and that differential expression of these 5 genes may 
even differentiate between PanIN and PDAC, suggesting 
dynamic, malignancy-related changes of these 5 genes 
during PDAC development.
qRT-PCR validation of the 5-gene PDAC 
classifier in retrospective FFPE patient samples 
demonstrates overexpression of the 5 genes in 
PDAC as compared to pancreatitis or healthy 
pancreas
To determine whether the five PDAC classifier 
genes indeed are higher expressed in PDAC than normal 
pancreas or benign pancreatic lesions, we developed 
a qRT-PCR assay for the five genes and evaluated the 
expression pattern of the 5-gene PDAC classifier in 22 
microdissected paired retrospective FFPE patient samples 
containing PDAC and matched non-tumor normal 
pancreatic tissue (9 samples) or matched pancreatitis 
tissue (13 samples) (Figure 5). Relative quantity (RQ) 
values were calculated by using the matched normal or 
pancreatitis tissue as the baseline to reflect the fold change 
in tumor samples. In all 22 matched pairs at least 4 of 
the 5 genes were elevated in pancreatic tumor tissue as 
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Figure 4: Performance and expression of 5-gene PDAC classifier on independent validation sets. A. Diagnostic performance 
of 5-gene PDAC classifier on five independent validation sets of normal and PDAC tissue samples. PPV = positive predictive value, NPV = 
negative predictive value. B. Diagnostic performance of the 5-gene PDAC classifier on Pancreatitis vs. Pancreatic Cancer dataset (Left) and 
on a dataset of normal pancreatic duct compared to LIGD-IPMN, HGD-IPMN, and InvCa-IPMN (Right). C. ROC curves for the different 
independent validation datasets. D. Hierarchical clustering analysis showing performance and expression of the 5-gene PDAC classifier on 
normal pancreatic duct compared to LIGD-IPMN, HGD-IPMN, and InvCa-IPMN samples. Red = upregulated, Blue = downregulated (Left 
Heatmap). Cross-species performance of the 5-gene PDAC classifier on a GEM mouse model of PDAC (Right Heatmap). Hierarchical 
clustering of pancreatic tissue samples from three mice each for normal pancreas, PanIN and PDAC across the 5-gene PDAC panel. Red 
= upregulated, Blue = downregulated. 
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compared to normal or pancreatitis tissue, and the box plots 
reflecting the relative expression of each gene compared 
to either matched normal or pancreatitis demonstrate 
clear discrimination, providing strong support that these 
5 genes are selectively overexpressed in PDAC (Figure 
5). Most importantly, this differential expression of the 5 
genes was validated in PDAC compared to pancreatitis, 
a clinically highly relevant differential diagnosis. All five 
genes showed elevated average expression in PDAC tissue 
compared to normal pancreas or pancreatitis tissue. The 
degree of upregulation when compared to normal tissue 
was significantly higher in three (POSTN, SERPINB5, 
TMPRSS4) of five genes than compared to pancreatitis, 
suggesting that POSTN, SERPINB5 and TMPRSS4 
expression increase gradually from healthy pancreas to 
pancreatitis to PDAC. AHNAK2 and ECT2 also showed 
elevated levels of expression in the matched PDAC tissue 
compared to normal or pancreatitis (fold change ~5-8), 
but the levels of these fold changes relative to normal and 
pancreatitis tissues were not significantly different.
Figure 5: qRT-PCR validation of 5-gene PDAC classifier on retrospective microdissected FFPE samples from patients 
with PDAC. Total RNA was isolated from 22 matched pairs of PDAC and pancreatitis (n = 13) or healthy pancreas (n = 9). FFPE tissue 
blocks were inspected by the pathologist and marked regions of PDAC, pancreatitis and healthy pancreas microdissected. QRTPCR was 
performed on each sample for POSTN, SERPINB5, AHNAK2, TMPRSS4 and ECT2 in duplicates. Box plots of fold change (RQ values) 
of PDAC samples relative to their matched pancreatitis or normal pancreas samples after normalization to GAPDH are shown. Average 
fold change values for each gene when the baseline was pancreatitis or normal tissue are indicated separately for each box plot. For each 
gene the ratio of the average fold change values for PDAC vs. pancreatitis or normal pancreas when the baseline was normal vs. pancreatitis 
tissue is indicated above the lines along with the statistical significance of the fold change value distributions in PDAC vs. normal or 
pancreatitis (**:p < 0.05, ns:non-significant).
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TMPRSS4 knockdown decreases PDAC cell 
migration, invasion, and anchorage-independent 
growth
To evaluate whether the PDAC classifier encodes 
proteins that are causally related to PDAC development 
and progression, we selected two of the genes, TMPRSS4, 
that has been previously linked to PDAC and other types of 
cancer [19-25] and ECT2, an oncogene that has previously 
been shown to be overexpressed in PDAC and other types 
of cancer [26]. TMPRSS4 protein expression in PDAC 
has not previously been studied. Western blot analysis 
Figure 6: Verification of TMPRSS4 function in various PDAC cells. A. TMPRSS4 protein expression across various PDAC cell 
lines and HPDE cells. Western Blot analysis of TMPRSS4 and beta actin. B. Cell viability of TMPRSS4 knockdown cells. Western Blot 
analysis of TMPRSS4 in whole cell lysates from BxPC-3 and Capan-1 cells 72 hours after shTMPRSS4 or shGFP infection (Top). Cell 
viability analysis of parental cells, shTMPRSS4 and shGFP cells using MTS assay (Bottom). C. + D. Knockdown of TMPRSS4 reduces 
migration and invasion of PDAC cells. Capan-1 cells or BxPC-3 cells stably transfected with shGFP-treated cells (control shRNA) or 
TMPRSS4 shRNA were placed in serum-free culture media and added into the upper compartment of a migration or invasion chamber. 
After 16 hours, cells in the upper chamber were removed and cells that had migrated or invaded through the pores of the membrane to the 
other side were fixed, stained, and counted. Cells in five different areas were quantified for migration and invasion studies. C, quantification 
of cells migrating through fibronectin-coated membranes. D, quantification of cells invading through Matrigel-coated membranes after 
16-h incubation and 10% serum as chemoattractant.
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verified increased TMPRSS4 protein expression in several 
PDAC cell lines compared to an immortalized pancreatic 
epithelial cell line, HPDE (Figure 6A). Particularly high 
TMPRSS4 expression was observed in MIA PaCa-2, 
Panc-1, Capan-1 and BxPC-3 PDAC cells. The functional 
relevance of TMPRSS4 or ECT2 in PDAC cells has not 
previously been determined, although TMPRSS4 has 
been demonstrated to induce invasion and epithelial-to-
mesenchymal transition ( EMT) of colorectal cancer cells 
[24, 25] and ECT2 overexpression has been primarily 
linked to cell proliferation, invasion and migration in 
lung cancer or glioma cells [26]. We infected two PDAC 
cell lines (Capan-1, BxPC-3) expressing high levels of 
TMPRSS4 with lentiviral vectors expressing shRNAs 
against TMPRSS4 (shTMPRSS4) or lentivirus expressing 
shGFP and Capan-1 cells with lentiviral vectors expressing 
shECT2 or scrambled shRNA. ShTMPRSS4 knocked 
down TMPRSS4 protein expression by more than 80% in 
both cell lines without affecting β-actin expression (Figure 
6B). TMPRSS4 knock-down decreased cell viability, as 
measured with the MTS assay, in Capan-1 and BxPC-3 
cells (Figure 6B). Similar to TMPRSS4, ECT2 knock-
down significantly decreased cell viability in Capan-1 
cells (Supplementary Figure S6A). 
TMPRSS4 knockdown reduced serum-induced 
migration of Capan-1 and BxPC-3 cells through the 
pores in a Transwell chamber assay by more than 80% 
compared with shGFP cells (Figure 6C). Because cell 
migration promotes tumor invasion, we tested the effect 
of TMPRSS4 knockdown on cell invasion using Matrigel-
coated Transwell chambers. TMPRSS4 knockdown 
compared with shGFP decreased Capan-1 and BxPC-
3 invasion by 60-90% after 16-h incubation (Figure 
6D). In contrast, knockdown of ECT2 did not have any 
significant effect on migration or invasion of Capan-1 
cells (Supplementary Figure S6C and D). These results 
demonstrate that TMPRSS4, but not ECT2 is an inducer 
of PDAC cell migration and invasion.
One of the hallmarks of malignancy is loss of 
anchorage-dependent growth as demonstrated by the 
ability to form colonies in soft agar. TMPRSS4 and 
ECT2 knockdown in PDAC cells significantly reduced 
anchorage-independent growth compared with the shGFP 
and parental cells in soft agar assays (Supplementary 
Figures. S5 and S6B). These results suggest that the 
5-gene PDAC classifier includes genes that are directly 
implicated in pathophysiological mechanisms of PDAC.
dIscussIon
We applied an innovative data mining approach 
to multiple transcriptome datasets followed by class 
prediction analysis and validation in independent datasets 
to discover candidate PDAC biomarkers [9, 27]. We 
identified a 10-gene and, as the most parsimonious and best 
performing panel and a subset of the 10-gene classifier, 
a 5-gene PDAC classifier that differentially diagnoses 
PDAC and precursor lesions with high accuracy. This 
5-gene PDAC classifier was validated in 9 independent 
human datasets, one dataset derived from a GEM mouse 
model of PDAC and by retrospective qRT-PCR analysis 
of patient-derived FFPE tissue samples. Most importantly, 
this 5-gene PDAC classifier discriminates between PDAC 
and pancreatitis and between PDAC precursor lesions 
and healthy pancreas. The 5-gene PDAC classifier 
encodes proteins involved in PDAC pathogenesis, such as 
TMPRSS4 and ECT2, that are overexpressed even at the 
earliest stages of PDAC development, suggesting causality 
during early PDAC development. 
The 5-gene PDAC classifier performed well 
across multiple microarray platforms from different 
laboratories and cross-species, using either whole tissue 
or microdissected tissue. While over 2500 candidate 
biomarkers have been associated with PDAC and some of 
these candidates are in various stages of evaluation, only 
CA19-9 is FDA-approved for PDAC [28]. Nevertheless, 
CA19-9 does not provide an accuracy high enough 
for screening, particularly for early detection or risk 
assessment. Currently, no diagnostic or predictive gene or 
protein expression biomarkers that accurately discriminate 
between healthy patients, benign, premalignant and 
malignant disease have been extensively validated. The 
goal of this study was to identify a biomarker panel with 
greater sensitivity and specificity compared to the primary 
biomarker currently used for PDAC, CA19-9. Our data 
suggest that a multiplex panel of biomarkers, rather than a 
single biomarker, is more likely to improve the specificity 
and selectivity for accurate detection of PDAC. Compared 
to the sensitivity of 79-81% and specificity of 82-90% for 
CA19-9 the sensitivity of our 5-gene PDAC classifier is 
superior [>85%] and with equal or better specificity [29].
We converted the in silico validation of publicly 
available transcriptome datasets into a qRT-PCR based 
assay for FFPE samples and confirmed in 22 pairs of 
retrospective patient samples that the 5-gene panel clearly 
discriminates between PDAC and pancreatitis or healthy 
pancreas. Importantly, expression of three of the five 
genes, POSTN, SERPINB5 and TMPRSS4, apparently 
increases gradually from healthy pancreas to pancreatitis 
and further rises between pancreatitis and PDAC. These 
three genes, thus, may reflect different pathophysiological 
functions from the two genes, AHNAK2 and ECT2 that 
are increased to a similar degree in PDAC when compared 
to pancreatitis or healthy pancreas. Differential diagnosis 
between PDAC and pancreatitis is critical, since patients 
with chronic pancreatitis are at increased risk of PDAC 
development and pathological discrimination between 
PDAC and pancreatitis can be challenging for definitive 
diagnosis of PDAC. Recent advances in endoscopic 
ultrasound (EUS) have yielded improved sensitivity 
for PDAC identification. Nevertheless, differentiating 
between PDAC and benign disease remains operator-
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dependent and sometimes challenging, frequently 
requiring multiple biopsies and procedures. Even after 
two EUS fine needle aspiration (FNA) biopsy procedures, 
diagnosis remains ambiguous for a subset of patients with 
a pancreatic abnormality [30], particularly in the setting of 
pancreatitis. This may result in diagnostic uncertainty and 
delays in potentially curative treatment. Thus, a key unmet 
medical need with immediate clinical utility is an effective 
cell-based diagnostic test that accurately differentiates 
between PDAC and non-malignant pancreatic disorders 
such as chronic pancreatitis.
Pre-operative diagnosis of pancreatic cancer is often 
limited by the performance of Endoscopic ultrasound-
guided fine-needle aspiration (EUS-FNA), a common 
diagnostic approach that may be inconclusive in up to 
20% of cases and for which inter-observer reliability is 
suboptimal even for biopsy evaluation [31-36]. More 
specifically, a wide range of performance parameters have 
been reported for malignancy diagnosis on cytopathologic 
analysis of EUS FNA: sensitivity from 73% to 94%, 
accuracy from 78% to 95% and a negative predictive value 
from 40% to 85% when specificity approaches 100% [31-
36]. Therefore, improved performance for the diagnosis 
of pancreatic lesions on aspiration or biopsy tissue is 
critical to early and effective treatment. The 5-gene PDAC 
classifier described in this manuscript may be first applied 
as a FNA-based real time PCR test to complement the 
pathologist and enhance positive and negative predictive 
value in diagnosing pancreatic cancer and differential 
diagnosis. 
Moreover, due to widespread use of abdominal 
cross-sectional imaging, pancreatic cysts are detected 
in ~2% of all patients who undergo abdominal imaging 
with computed tomography and ~15% of all patients who 
undergo an abdominal MRI. Once imaged, pancreatic 
cysts are frequently biopsied and classified as PanINs, 
MCNs and IPMNs. However, the guidelines with regards 
to monitoring and treatment of these cystic lesions remain 
unclear and no definitive diagnosis about malignancy or 
risk of malignancy can be made.
Frequently, EUS combined with FNA is used to 
visualize the pancreas from the duodenum or stomach 
but is sometimes challenged with diagnostic accuracy in 
detecting malignant lesions under 3 cm even by skilled 
clinicians. However, EUS-FNA has less than optimal 
accuracy for differentiating pancreatic cancer from chronic 
pancreatitis. Since only a small minority of these cysts, but 
still significant number, subsequently progress to cancer, 
there may be needless over- or under-treatment, and 
morbidity. Our 5-gene classifier may be able to be applied 
in the setting where FNAs are taken from cysts or other 
suspicious pancreatic lesions for differential diagnosis.
Above all, the 5-gene PDAC classifier accurately 
distinguishes premalignant and malignant pancreatic 
lesions such as PanIN, IPMN with low- to intermediate 
grade dysplasia, IPMN with high-grade dysplasia and 
IPMN with associated invasive carcinoma from healthy 
pancreas. In this context it is reassuring to observe that 
the 5-gene PDAC classifier performs equally well in the 
PDX1-Cre;LSL-KrasG12D mouse model of PDAC that 
phenocopies the human disease and allows evaluation of 
the different developmental stages of PDAC development, 
including PanIN, that are typically not detected and 
sampled in humans [37]. We discovered that all 5 genes 
are overexpressed already in PanIN, indicating that 
these 5 genes become dysregulated very early during 
PDAC development and could indeed assist in early 
detection of PDAC. IPMNs and other pancreatic cysts 
are frequent events in older patients (in some autopsy 
studies up to 24%). Imaging improvements have resulted 
in an increasing number of asymptomatic, incidentally 
discovered pancreatic cysts [38]. While many are benign, 
MCNs and IPMNs have a significant incidence (2.4-
13.5%) of either harboring malignant cells or progressing 
towards invasive cancer [39]. Consequently, pancreatic 
cysts cannot be ignored; however, current diagnostic 
tools are limited for accurately predicting their malignant 
potential. Survival upon surgical resection of non-
malignant lesions is close to 100% and after malignant 
transformation drops to 55-60% [40]. Resection of all 
pancreatic cysts is difficult due to relatively high rates 
of mortality (1-6%) and morbidity (35-51%) in elderly 
patients. A key challenge is how to prioritize the cysts that 
can be ignored or followed versus the ones that should 
be surgically resected. An early detection marker, one 
able to detect PDAC precursor lesions (IPMN, PanIN) 
with early malignant transformation or high risk for 
malignant transformation, would increase the likelihood 
of identifying such patients that may have localized 
disease amendable to curative surgery. Better diagnosis 
of borderline and invasive IPMNs and MCNs would 
be highly significant, and enable patients to choose the 
most appropriate course of action; this 5-gene PDAC 
classifier may provide such a risk assessment. Discovery 
and validation of a distinct set of sensitive and specific 
biomarkers for risk-stratifying patients at high risk for 
developing PDAC would eventually enable routine 
screening of high risk groups (i.e., incidental detection 
of pancreatic lesions, family history of PDAC, hereditary 
syndromes (VHL), chronic pancreatitis, type 3c diabetes, 
smokers, BRCA2 carriers, etc). 
While other studies have performed meta-analysis 
of transcriptome data for PDAC, such as a recent meta-
analysis study that identified more than 800 genes that 
are overexpressed in PDAC [41], none of these studies 
including this latest report attempted to select any 
genes as PDAC predictors. In contrast, there has been 
significant progress in identifying circulating miRNAs 
that distinguish PDAC from chronic pancreatitis and 
healthy patients in plasma and bile [42]. A 5 miRNA panel 
diagnosed PDAC with 95% sensitivity and specificity 
in a cohort that included healthy, chronic pancreatitis 
Oncotarget23277www.impactjournals.com/oncotarget
and PDAC patients [42]. However, there is no evidence 
whether these miRNAs would diagnose early stages of 
PDAC.
The set of PDAC biomarkers identified in this study 
may be regulated by a common set of upstream regulatory 
transcription factors. However, based on available data 
and Ingenuity upstream regulator analysis no common 
upstream regulator or transcription factor was identified 
by us. This is no surprise, since AHNAK2 and TMPRSS4 
have rather limited information available. Using the 
Transfac database we have analyzed the promoter regions 
between -2000 and +100 for the 5 genes for common 
transcription factor binding sites. Transfac analysis 
identified 6 transcription factors (ZNF333, Ikaros, ING4, 
MZF-1, CRX, NF-AT1) with predicted binding sites in 
4 out of the 5 genes, suggesting that these transcription 
factors may be common to these PDAC classifier genes 
(data not shown). Nevertheless, further studies are needed 
to explore the potential role of these transcription factors 
in controlling expression of these genes in PDAC.
To determine whether the set of biomarkers 
encoded by our PDAC classifier may also reflect key 
pathophysiological pathways associated with PDAC 
development or progression that may be candidate 
therapeutic targets (i.e., similar to value of Her2/neu as a 
biomarker and therapeutic target), we reviewed available 
public data for the classifier genes. 
The 5-gene classifier includes two genes, TMPRSS4 
and POSTN, previously identified as candidate PDAC 
biomarkers further validating our innovative meta-
analysis strategy to select significant PDAC biomarkers. 
Several genes of our 5-gene classifier have been linked 
to tumorigenesis, indicating a causal role in PDAC 
development and progression. 
Most of the classifier genes (TMPRSS4, POSTN, 
SERPINB5) have been linked to migration, invasion, 
adhesion and metastasis of PDAC or other cancers, 
specifically associated with extracellular matrix and 
tumor microenvironment. This may not be surprising 
due to the dense, desmoplastic stroma associated with 
PDAC that may prevent efficient drug delivery [43]. 
However, these biological functions would be anticipated 
to be involved in PDAC progression rather than early 
stages of PDAC development. To explore this aspect in 
more detail we evaluated the expression levels of these 
“PDAC progression” genes in the transcriptome datasets 
comparing PDAC precursors (LIGD-IPMN, HGD-IPMN) 
and InvCa-IPMN to normal pancreas, and PDAC vs. 
PanIN vs. healthy pancreas in the GEM model) (Figure 
4) [15]. TMPRSS4, SERPINB5, ECT2, and AHNAK2 
are overexpressed in LIGD-IPMN, HGD-IPMN, and 
InvCa-IPMN as well as in PanINs, as compared to normal 
pancreas, demonstrating that enhanced expression of 
multiple genes linked to metastasis and PDAC progression 
occurs early on during malignant development. This 
analysis indicates that the PDAC classifier may reflect 
some driving early defects during PDAC development.
No details about AHNAK2 function are available, 
but its closest relative AHNAK is involved in cancer 
migration and EMT, providing support that AHNAK2 
may elicit similar features [44]. Periostin (POSTN), 
frequently overexpressed in melanoma, pancreatic, 
esophageal, prostate, and liver cancer [45-47], promotes 
invasiveness and metastasis of PDAC [48] and other 
cancer types [49]. Maspin (SERPINB5) overexpression 
correlates with increased metastasis and poor outcome 
in PDAC and gastric cancer [50-52]. But SERPINB5 
is regarded as a metastasis suppressor in breast and 
colorectal cancer [50]. For PDAC, conflicting roles of 
SERPINB5 have been described: SERPINB5-transfected 
PDAC cells exhibit reduced invasive ability [53], but 
SERPINB5 overexpression in PDAC is an independent 
adverse prognosticator for postoperative survival [51]. The 
detection of SERPINB5 in high-grade PanIN and PDAC 
and its lack of expression in normal pancreatic tissues and 
chronic pancreatitis suggest that SERPINB5 upregulation 
occurs early during the multi-step progression of PDAC 
[53, 54]. The oncogene ECT2 is overexpressed in several 
cancer types including PDAC, and correlates with poor 
outcome in glioma and gastric cancer [26]. We now 
provide the first evidence that ECT2 may play a role in 
PDAC viability and soft agar growth. 
 TMPRSS4, a protease of the Type II transmembrane 
serine protease (TTSP) family, is highly expressed in 
pancreatic, thyroid, lung, gastric, cervical, breast, and 
colorectal cancer tissues and directly correlates with 
poor outcome [19-25]. TMPRSS4 expression correlates 
with the metastatic potential of several cancer cell lines, 
and our cell-based studies demonstrate that TMPRSS4 
induces migration, invasion and anchorage-independent 
growth [20, 24, 25]. Moreover, we provide the first qRT-
PCR-based analysis for enhanced TMPRSS4 expression in 
microdissected PDAC tissue as compared to pancreatitis 
or healthy pancreas. TMPRSS4 promotes invasion, 
migration and metastasis of colorectal and lung cancer 
cells by facilitating an EMT [24, 25]. Multiple downstream 
signaling pathways, including focal adhesion kinase 
(FAK), extracellular signal-regulated kinase (ERK), Akt, 
Src and Rac1, and integrin alpha5 expression are activated 
by TMPRSS4 expression in lung and colon cancer cells 
[20, 25, 55]. 
In conclusion, we have identified a new multiplex 
panel of biomarkers for early detection of PDAC that 
can be developed as a diagnostic assay, facilitating early 
diagnosis and screening for malignant transition of 
potential PDAC precursor lesions and for high risk patient 
groups. Since the number of samples evaluated in this 
study for discrimination of early stages (PanIN, IPMN 
with dysplasia) of PDAC is relatively small, we will have 
to further establish the accuracy on larger numbers of 
such specimens. Our data combined with the supportive 
published evidence suggest that the five biomarkers 
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identified in our PDAC classifier can be exploited for 
development of new drugs targeting these markers, 
since these genes are overexpressed in precursor lesions 
and have a strong rationale for involvement in PDAC 
tumorigenesis and metastasis. 
MATERIALS AND METhODS
Meta-analysis to identify optimal PDAC 
biomarker panel
Dataset identification
Four training sets [GSE18670, E-MEXP-950, 
GSE15471, GSE16515] and nine independent validation 
sets [GSE32676, GSE28735, GSE11838, GSE9599, 
E-MEXP-2894, E-TABM-145, E-MEXP-1121, 
GSE19650, GSE12630] of transcriptome data for human 
pancreas specimens and one dataset of transcriptome data 
from the PDX1-Cre; LSL-KrasG12D genetically engineered 
mouse (GEM) model of PDAC (GSE33322) were 
selected from publicly available microarray repositories 
as described in Supplementary Material and Methods.
Quality control and outlier analysis
Stringent quality control and outlier analysis was 
performed on all datasets used for training and validation 
to remove low quality arrays from the meta-analysis as 
described in Supplementary Material and Methods.
Mapping of platform specific identifiers to entrez 
gene IDs
To facilitate collation of the differentially expressed 
genes identified by analysis of individual datasets, the 
probe-level identifiers associated with each dataset were 
annotated with corresponding gene-level identifiers 
as described in detail in Supplementary Material and 
Methods. 
Pre-processing and normalization of microarray 
datasets
Potential bias introduced by the range of 
methodologies used in the original microarray studies, 
including various experimental platforms and analytic 
methods, was controlled by applying a uniform 
normalization, preprocessing and statistical analysis 
strategy to each dataset using the Frozen Robust Multi-
array Average (fRMA) algorithm with rma background 
correction and Z-score as described in Supplementary 
Material and Methods. 
Differential gene expression analysis
For training set differential expression analysis, 
the two sample classes were normal pancreas (NP) 
and PDAC and the null hypothesis was “no difference 
in gene expression exists between the NP and PDAC 
sample classes”. The differentially expressed transcripts 
were identified using the linear model microarray 
analysis software package (LIMMA) and on the basis of 
absolute fold change of at least 1.5 and Benjamini and 
Hochberg corrected p-value <.05. Differentially expressed 
genes with concordant directionality (upregulation or 
downregulation) in three out of four datasets were used 
for training the PDAC classifier. 
Training and independent validation of PDAC 
classifier using support vector machine
The 409 genes differentially expressed in at least 
3 out of 4 datasets were used for classifier generation 
by implementing the Support Vector Machines (SVM) 
approach using Bioconductor and using 0 as the threshold. 
Classifiers were trained using normalized, preprocessed 
gene expression values. Performance of classifiers in 
the training sets was evaluated using internal Leave-
One-Out Cross-Validation (LOOCV). The performance 
of classifiers was measured using threshold-dependent 
(e.g. sensitivity, specificity, accuracy) and threshold-
independent receiver operating characteristic (ROC) 
analysis. In ROC analysis, the area under the curve (AUC) 
provides a single measure of overall prediction accuracy. 
We developed biomarker panels ranging from 2 to 40 
genes to develop highly accurate biomarker panels with a 
minimum number of genes. The biomarker panel with the 
highest performance in the training sets was chosen for 
assessment of predictive power in 9 independent validation 
datasets using threshold-dependent and -independent 
(AUC) measures. For independent validation the same 
threshold selected for the training set was applied.
To further compare the performance of actual 
classifiers with random classifiers we performed 
randomization analysis. 1000 random classifiers of 
the size of actual classifiers were developed, and their 
performances were compared. Statistical testing (p-value) 
evaluated the hypothesis that random classifiers had the 
same or better performance than the actual classifier. 
Correlative laboratory evaluation
Antibodies, reagents, lentiviral production and 
infection, cell culture, cell-based assays (proliferation, 
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migration, invasion, soft agar growth), and Western blot 
analysis are described in Supplementary Material and 
Methods.
Quantitative real-time PCR (qRT-PCR) analysis 
of FFPE samples
qRT-PCR analysis was performed on RNA isolated 
from core punches, restricted to tumor regions that a 
fellowship-trained, gastrointestinal and hepato-pancreato-
biliary pathologist (EUY) marked as PDAC, pancreatitis 
or healthy pancreas, from human formalin-fixed paraffin 
embedded (FFPE) tissue obtained from 22 PDAC patients 
(9 well-differentiated, 9 moderately-differentiated, 3 
poorly differentiated, 1 other) as described in detail in 
Supplementary Material and Methods. 
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